Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04814108 · ClinicalTrials.gov registry record · Phase 2

A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

A Phase 2 study of Uterine Serous Carcinoma, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
20
Study locations

NCT04814108 is a Phase 2 study of Uterine Serous Carcinoma that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 92 participants, roughly in line with the 89-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target. The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04814108, a Phase 2 study of Uterine Serous Carcinoma, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

Conditions Studied

Uterine Serous Carcinoma

Interventions

  • DRUG Azenosertib

Study Locations (20)

Arizona

  • Honor Health - Phoenix
  • Arizona Oncology Associates Wilmot HOPE - Tucson
  • Banner University Medical Center Tucson - Tucson

Florida

  • Mount Sinai Medical Center - Miami Beach
  • Sarasota Memorial Hospital - Sarasota
  • University of South Florida - Tampa

Michigan

  • Oakland Medical Group - Detroit
  • Corewell Health - Grand Rapids
  • Revive Clinical Research - Sterling

California

  • University of California Irvine Medical Center - Orange
  • University of California San Francisco at Mission Bay - San Francisco

Georgia

  • Northside Hospital - Atlanta
  • Georgia Cancer Center at Augusta University - Augusta

Maryland

  • Maryland Oncology Hematology - Annapolis
  • University of Maryland Medical Center - Baltimore

Alaska

  • Alaska Women's Cancer Care - Anchorage

Illinois

  • Northwestern University - Evanston

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2021-07-28
Est. Completion 2025-10-22
Phase Phase 2

Sponsor

K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04814108

The ClinicalTrials.gov registry entry for NCT04814108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 89-participant average among 4 other Uterine Serous Carcinoma trials with a reported enrollment target. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Uterine Serous Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Azenosertib is the first listed.

NCT04814108 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Arizona, Florida, Michigan.

Frequently Asked Questions

What is clinical trial NCT04814108 about?

NCT04814108 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma". This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).

What is the current status of trial NCT04814108?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2021-07-28. Estimated completion is 2025-10-22.

What conditions does trial NCT04814108 study?

This clinical trial studies the following conditions: Uterine Serous Carcinoma.

What interventions are being tested in trial NCT04814108?

The interventions under investigation include: Azenosertib (DRUG).

Who is sponsoring clinical trial NCT04814108?

This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04814108 being conducted?

This trial has 20 study locations across Alaska, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Uterine Serous Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Uterine Serous Carcinoma

All registered trials for this condition

Alaska

All trials with a study site in Alaska

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.